Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.22.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Operating Activities:      
Consolidated net income (loss) $ (41,597) $ 46,082 $ (17,282)
Adjustments to reconcile consolidated net income (loss) to cash provided by operating activities:      
Depreciation and amortization of intangibles 25,095 23,292 30,268
Asset impairments 3,100 24,356
Income from loan forgiveness (9,860)
Fair value adjustments 9,959
(Gain) loss on (sale) disposal of assets 2,230 (4,571) (1,580)
Inventory valuation 4,612 (257)
Gains on derivative instruments (19,263) (21,619) (14,780)
Amortization of deferred financing costs 177 778 1,394
Amortization of debt discounts (premiums) 126 (230) (230)
Noncash compensation 3,333 2,883 2,679
Bad debt expense (recovery) (217) 158 245
Interest expense added to senior notes 133
Changes in operating assets and liabilities:      
Accounts receivable 23,967 (43,554) 30,571
Inventories (15,479) (16,448) 19,090
Other current assets 7,690 38,989 1,507
Operating leases (5,128) (4,216) (4,751)
Assets held-for-sale (3,483) 1,012
Liabilities held-for-sale 2,305 9,110
Accounts payable and accrued expenses 20,503 13,215 (19,763)
Net cash provided by operating activities 6,049 26,821 71,681
Investing Activities:      
Proceeds from principal payments on notes receivable 14,766
Purchase of Eagle Alcohol, net of cash acquired (14,685)
Proceeds from sale of Stockton 24,000
Proceeds from sale of Madera 19,500
Proceeds from sale of interests in PAL 19,896
Proceeds from Magic Valley asset sale 10,000
Additions to property and equipment (37,744) (16,384) (6,580)
Net cash provided by (used in) investing activities (37,663) 27,116 23,316
Financing Activities:      
Net proceeds from term loan 59,100
Net proceeds from (payments on) Kinergy’s line of credit (32,325) 17,889 (45,826)
Debt issuance costs (5,171)
Preferred stock dividend payments (1,265) (2,853)
Stock repurchases (1,325)
Proceeds from issuances of common stock and warrants 462 75,829
Proceeds from warrant exercises 5,500
Proceeds from CARES Act loans 9,860
Payments on plant borrowings (29,964) (71,536)
Payments on senior notes (25,533) (40,249)
Net cash provided by (used in) financing activities 19,014 (39,999) (66,422)
Net increase (decrease) in cash, cash equivalents and restricted cash (12,600) 13,938 28,575
Cash, cash equivalents and restricted cash at beginning of period 62,125 48,187 19,612
Cash, cash equivalents and restricted cash at end of period 49,525 62,125 48,187
Reconciliation of total cash, cash equivalents and restricted cash:      
Cash and cash equivalents 36,456 50,612 47,667
Restricted cash 13,069 11,513 520
Total cash, cash equivalents and restricted cash 49,525 62,125 48,187
Supplemental Information:      
Interest paid (net of capitalized interest) 2,208 3,489 17,469
Capitalized interest 720 628 224
Income tax payments (refunds) 2,262 448 (641)
Noncash financing and investing activities:      
Accrued preferred stock dividends $ 1,268